

DAFTAR PUSTAKA

- Abdelraheem, W. M., Abdelkader, A. E., Mohamed, E. S., & Mohammed, M. S. (2020). Detection of biofilm formation and assessment of biofilm genes expression in different *Pseudomonas aeruginosa* clinical isolats. *Meta Gene*, 23. <https://doi.org/10.1016/j.mgene.2020.100646>
- Aka, S. T., & Haji, S. H. (2015). Sub-MIC of antibiotics induced biofilm formation of *Pseudomonas aeruginosa* in the presence of chlorhexidine. *Brazilian Journal of Microbiology*, 46(1), 149–154. <https://doi.org/10.1590/S1517-838246120140218>
- Aleanizy, F. S., Alqahtani, F. Y., Eltayb, E. K., Alrumikan, N., Almebki, R., Alhossan, A., Almangour, T. A., & AlQahtani, H. (2021). Evaluating the effect of antibiotics sub-inhibitory dose on *Pseudomonas aeruginosa* quorum sensing dependent virulence and its phenotypes. *Saudi Journal of Biological Sciences*, 28(1), 550–559. <https://doi.org/10.1016/j.sjbs.2020.10.040>
- Aminov, R. (2017). History of antimicrobial drug discovery: Major classes and health impact. In *Biochemical Pharmacology* (Vol. 133, pp. 4–19). Elsevier Inc. <https://doi.org/10.1016/j.bcp.2016.10.001>
- Andersson, D. I., Nicoloff, H., and Hjort, K. (2019). Mechanisms and clinical relevance of bacterial heteroresistance. *Nat. Rev. Microbiol.* 17, 479–496. doi:10.1038/s41579-019-0218-1
- Arabameri, N., Heshmatipour, Z., Ardebili, S. E., & Bidhendi, Z. J. (2021). The role of gene mutations (*GyrA*, *parc*) in resistance to ciprofloxacin in clinical isolats of *Pseudomonas aeruginosa*. *Iranian Journal of Pathology*, 16(4), 426–432. <https://doi.org/10.30699/ijp.2021.520570.2542>
- Band, V. I., and Weiss, D. S. (2019). Heteroresistance: a cause of unexplained antibiotic treatment failure? *PLoS Pathog.* 15:e1007726. doi: 10.1371/journal.ppat.1007726
- Cole, S. J., Records, A. R., Orr, M. W., Linden, S. B., & Lee, V. T. (2014). Catheter-associated urinary tract infection by *Pseudomonas aeruginosa* is mediated by

- exopolysaccharide-independent biofilms. *Infection and Immunity*, 82(5), 2048–2058. <https://doi.org/10.1128/IAI.01652-14>
- CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed. CLSI supplement M100. Wayne, PA : Clinical and Laboratory Standards Institute; 2020.
- de Sousa, T., Hébraud, M., Enes Dapkevicius, M. L. N., Maltez, L., Pereira, J. E., Capita, R., Alonso-Calleja, C., Igrejas, G., & Poeta, P. (2021). Genomic and metabolic characteristics of the pathogenicity in *Pseudomonas aeruginosa*. In *International Journal of Molecular Sciences* (Vol. 22, Issue 23). MDPI. <https://doi.org/10.3390/ijms222312892>
- Donlan, R.M dan Costerton, J.W. 2002. Biofilms: Survival Mechanisms Of Clinically Relevant Microorganisms. *Clin. Microbiol. Rev.* 15: 167–193.
- Drago, L., Mattina, R., Legnani, D., Romano, C. L., Vianello, E., Ricci, C., & De Vecchi, E. (2011). Modulation of biofilm of strains isolated from patients with chronic obstructive pulmonary disease by levofloxacin, moxifloxacin, ciprofloxacin, amoxicillin/clavulanic acid and ceftriaxone. *International Journal of Immunopathology and Pharmacology*, 24, 1027–1035. <https://doi.org/10.1177/039463201102400420>
- Elhosseini, M. A., El-Banna, T. E., Sonbol, F. I., & El-Bouseary, M. M. (2024). Potential antivirulence activity of sub-inhibitory concentrations of ciprofloxacin against *Proteus mirabilis* isolates: an in-vitro and in-vivo study. *Annals of Clinical Microbiology and Antimicrobials*, 23(1). <https://doi.org/10.1186/s12941-024-00704-4>
- Emami, S., Nikokar, I., Ghasemi, Y., Ebrahimpour, M., Ebrahim-Saraie, H. S., Araghian, A., Faezi, S., Farahbakhsh, M., & Rajabi, A. (2015). Antibiotic resistance pattern and distribution of *pslA* gene among biofilm producing *Pseudomonas aeruginosa* isolated from waste water of a burn center. *Jundishapur Journal of Microbiology*, 8(11). <https://doi.org/10.5812/jjm.23669>

Evans, T. J. (2015). Small colony variants of *Pseudomonas aeruginosa* in chronic bacterial infection of the lung in *cystic fibrosis*. *Future Microbiology*, 10, 231–239. <https://doi.org/10.2217/fmb.14.107>

GBD 2019 Demographics Collaborators. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020; 396:1160-203

Ghafoor A, Hay ID, Rehm BH. Role of exopolysaccharides in *Pseudomonas aeruginosa* biofilm formation and architecture. *Appl Environ Microbiol.* 2011;**77**(15):5238–46. doi: 10.1128/AEM.00637-11. [PubMed: 21666010]

Ghafoor, A., Jordens, Z., & Rehman, B. A. B. (2013). Role of *pelF* in *pel* polysaccharide biosynthesis in *Pseudomonas aeruginosa*. *Applied and Environmental Microbiology*, 79(9), 2968–2978. <https://doi.org/10.1128/AEM.03666-12>

Grainha, T., Jorge, P., Alves, D., Lopes, S. P., & Pereira, M. O. (2020). Unraveling *Pseudomonas aeruginosa* and *Candida albicans* Communication in Coinfection Scenarios: Insights Through Network Analysis. *Frontiers in Cellular and Infection Microbiology*, 10. <https://doi.org/10.3389/fcimb.2020.550505>

Irie, Y., La Mensa, A., Murina, V., Hauryliuk, V., Tenson, T., & Shingler, V. (2020). Hfq-Assisted RsmA Regulation Is Central to *Pseudomonas aeruginosa* Biofilm Polysaccharide PEL Expression. *Frontiers in Microbiology*, 11. <https://doi.org/10.3389/fmicb.2020.482585>

Jones, C. J., Grotewold, N., Wozniak, D. J., & Gloag, E. S. (2022). *Pseudomonas aeruginosa* Initiates a Rapid and Specific Transcriptional Response during Surface Attachment. *Journal of Bacteriology*, 204(5). <https://doi.org/10.1128/jb.00086-22>

Kamali, E., Jamali, A., Ardebili, A., Ezadi, F., & Mohebbi, A. (2020). Evaluation of antimicrobial resistance, biofilm forming potential, and the presence of biofilm-

related genes among clinical isolats of *Pseudomonas aeruginosa*. *BMC Research Notes*, 13(1). <https://doi.org/10.1186/s13104-020-4890-z>

Kaplan, J. B., Jabbouri, S., & Sadovskaya, I. (2011). Extracellular DNA-dependent biofilm formation by *Staphylococcus epidermidis* RP62A in response to subminimal inhibitory concentrations of antibiotics. *Research in Microbiology*, 162(5), 535–541. <https://doi.org/10.1016/j.resmic.2011.03.008>

Karuniawati, A., Saharman, Y. R., & Lestari, D. C. (n.d.). *Detection of Carbapenemase Encoding Genes in Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii Isolats from Patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011*.

Kato, H., & Hamada, Y. (2022). Amikacin Therapy in Japanese Pediatric Patients: Narrative Review. In *International Journal of Environmental Research and Public Health* (Vol. 19, Issue 4). MDPI. <https://doi.org/10.3390/ijerph19041972>

Kim, S. K., and Lee, J. H. (2016). Biofilm dispersion in *Pseudomonas aeruginosa*. *J. Microbiol.* 54, 71–85. doi: 10.1007/s12275-016-5528-7

Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., and Hall-Stoodley, L. (2017). Targeting microbial biofilms: current and prospective therapeutic strategies. *Nat. Rev. Microbiol.* 15, 740–755. doi: 10.1038/nrmicro.2017.99

Kunz Coyne, A. J., el Ghali, A., Holger, D., Rebold, N., & Rybak, M. J. (2022). Therapeutic Strategies for Emerging Multidrug-Resistant *Pseudomonas aeruginosa*. In *Infectious Diseases and Therapy* (Vol. 11, Issue 2, pp. 661–682). Adis. <https://doi.org/10.1007/s40121-022-00591-2>

Lam, A. K., Panlilio, H., Pusavat, J., Wouters, C. L., Moen, E. L., and Rice, C. V. (2020). Overcoming multidrug resistance and biofilms of *Pseudomonas aeruginosa* with a single dual-function potentiator of β -lactams. *ACS Infect. Dis.* 6, 1085–1097. doi: 10.1021/acsinfecdis.9b00486

- Lanotte P, Watt S, Mereghetti L, Dartiguelongue N, Rastegar-Lari A, Goudeau A, Quentin R: Genetic features of *Pseudomonas aeruginosa* isolats from *cystic fibrosis* patients compared with those of isolats from other origins. *J Med Microbiol* 53, 73–81 (2004)
- Lebeaux, D., Ghigo, J.-M., & Beloin, C. (2014). Biofilm-Related Infections: Bridging the Gap between Clinical Management and Fundamental Aspects of Recalcitrance toward Antibiotics. *Microbiology and Molecular Biology Reviews*, 78(3), 510–543. <https://doi.org/10.1128/mmmbr.00013-14>
- Li, W. R., Zhang, Z. Q., Liao, K., Wang, B. B., Liu, H. Z., Shi, Q. S., Huang, X. bin, & Xie, X. B. (2022). *Pseudomonas aeruginosa* heteroresistance to levofloxacin caused by upregulated expression of essential genes for DNA replication and repair. *Frontiers in Microbiology*, 13. <https://doi.org/10.3389/fmicb.2022.1105921>
- Liao, C., Huang, X., Wang, Q., Yao, D., & Lu, W. (2022). Virulence Factors of *Pseudomonas aeruginosa* and Antivirulence Strategies to Combat Its Drug Resistance. In *Frontiers in Cellular and Infection Microbiology* (Vol. 12). Frontiers Media S.A. <https://doi.org/10.3389/fcimb.2022.926758>
- LiReichhardt, C., & Parsek, M. R. (2019). Confocal laser scanning microscopy for analysis of *Pseudomonas aeruginosa* biofilm architecture and matrix localization. In *Frontiers in Microbiology* (Vol. 10, Issue APR). Frontiers Media S.A. <https://doi.org/10.3389/fmicb.2019.00677>
- Marsifah, T., 2024. *Analisis Ekspresi Gen dan Aktivitas Pembentukan Biofilm pada Kultur Polimikrobia Isolat Klinis Pseudomonas aeruginosa dan Candida albicans*. Tesis (Magister Ilmu Biomedik). Universitas Gadjah Mada.
- Nouri, R., Ahangarzadeh Rezaee, M., Hasani, A., Aghazadeh, M., & Asgharzadeh, M. (2016). The role of *gyrA* and *parC* mutations in fluoroquinolones-resistant *Pseudomonas aeruginosa* isolats from Iran. *Brazilian Journal of Microbiology*, 47(4), 925–930. <https://doi.org/10.1016/j.bjm.2016.07.016>

- Olivares, E., Badel-Berchoux, S., Provot, C., Prevost, G., Bernardi, T., and Jehl, F. (2019). Clinical impact of antibiotics for the treatment of *Pseudomonas aeruginosa* biofilm infections. *Front. Microbiol.* 10, 2894. doi: 10.3389/fmicb.2019.02894
- Otani, S., Hiramatsu, K., Hashinaga, K., Komiya, K., Umeki, K., Kishi, K., & Kadota, J. ichi. (2018). Sub-minimum inhibitory concentrations of ceftazidime inhibit *Pseudomonas aeruginosa* biofilm formation. *Journal of Infection and Chemotherapy*, 24(6), 428–433. <https://doi.org/10.1016/j.jiac.2018.01.007>
- Overhage J, Schemionek M, Webb JS, Rehm BH. Expression of the *psl* operon in *Pseudomonas aeruginosa* PAO1 biofilms: *PslA* performs an essential function in biofilm formation. *Appl Environ Microbiol.* 2005;**71**(8):4407–13. doi: 10.1128/AEM.71.8.4407-
- Pouget, C., Dunyach-Remy, C., Pantel, A., Schuldiner, S., Sotto, A., & Lavigne, J. P. (2020). Biofilms in diabetic foot ulcers: Significance and clinical relevance. In *Microorganisms* (Vol. 8, Issue 10, pp. 1–15). MDPI AG. <https://doi.org/10.3390/microorganisms8101580>
- Pancu, D. F., Scurtu, A., Macasoi, I. G., Marti, D., Mioc, M., Soica, C., Coricovac, D., Horhat, D., Poenaru, M., & Dehelean, C. (2021). Antibiotics: Conventional therapy and natural compounds with antibacterial activity-a pharmaco-toxicological screening. *Antibiotics*, 10(4). <https://doi.org/10.3390/antibiotics10040401>
- Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J., and Cheng, Z. (2019). Antibiotic resistance in *Pseudomonas aeruginosa*: Mechanisms and alternative therapeutic strategies. *Biotechnol. Adv.* 37, 177–192. doi: 10.1016/j.biotechadv.2018.11.013
- Panwar, R., Gehlot, V., kumar, R., Maherchandani, S., & sant, B. (2020). Qualitative and Quantitative Biofilm Assay of *Pseudomonas aeruginosa* Isolats from Clinical Samples. *International Journal of Current Microbiology and Applied Sciences*, 9(6), 1708–1713. <https://doi.org/10.20546/ijcmas.2020.906.211>
- Rajabi, H., Salimizand, H., Khodabandehloo, M., Fayyazi, A., & Ramazanzadeh, R. (2022). Prevalence of *algD*, *pslD*, *pelF*, *Ppgl*, and *PAPI-1* Genes Involved in Biofilm

Formation in Clinical *Pseudomonas aeruginosa* Strains. *BioMed Research International*, 2022. <https://doi.org/10.1155/2022/1716087>

- Ramírez-Estrada, S., Borgatta, B., & Rello, J. (2016). *Pseudomonas aeruginosa* ventilator-associated pneumonia management. In *Infection and Drug Resistance* (Vol. 9, pp. 7–18). Dove Medical Press Ltd. <https://doi.org/10.2147/IDR.S50669>
- Ramirez, M. S., & Tolmasky, M. E. (2017). Amikacin: Uses, resistance, and prospects for inhibition. In *Molecules* (Vol. 22, Issue 12). MDPI AG. <https://doi.org/10.3390/molecules22122267>
- Rehman, A., Patrick, W. M., & Lamont, I. L. (2019). Mechanisms of ciprofloxacin resistance in *Pseudomonas aeruginosa*: New approaches to an old problem. In *Journal of Medical Microbiology* (Vol. 68, Issue 1, pp. 1–10). Microbiology Society. <https://doi.org/10.1099/jmm.0.000873>
- Romanova, Yu. M., Smirnova T. A., Andreev, A. L., Il'ina T. S., Didenko L. V., dan Gintsburg, A. L. 2006. Formation of Biofilms as an Example of the Social Behavior of Bacteria. *Microbiology*. 75(4) : 481-485.
- Roudashti, S., Zeighami, H., Mirshahabi, H., Bahari, S., Soltani, A., & Haghi, F. (2017). Synergistic activity of sub-inhibitory concentrations of curcumin with ceftazidime and ciprofloxacin against *Pseudomonas aeruginosa* quorum sensing related genes and virulence traits. *World Journal of Microbiology and Biotechnology*, 33(3). <https://doi.org/10.1007/s11274-016-2195-0>
- Roy, R., Tiwari, M., Donelli, G., and Tiwari, V. (2018). Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action. *Virulence* 9, 522–554. doi: 10.1080/21505594.2017.1313372
- Rumbaugh, K. P., and Sauer, K. (2020). Biofilm dispersion. *Nat. Rev. Microbiol.* 18, 571–586. doi: 10.1038/s41579-020-0385-0
- Rusu, A., Lungu, I. A., Moldovan, O. L., Tanase, C., & Hancu, G. (2021). Structural characterization of the millennial antibacterial (Fluoro)quinolones—shaping the

- fifth generation. In *Pharmaceutics* (Vol. 13, Issue 8). MDPI. <https://doi.org/10.3390/pharmaceutics13081289>
- Sada, M., Kimura, H., Nagasawa, N., Akagawa, M., Okayama, K., Shirai, T., Sunagawa, S., Kimura, R., Saraya, T., Ishii, H., Kurai, D., Tsugawa, T., Nishina, A., Tomita, H., Okodo, M., Hirai, S., Ryo, A., Ishioka, T., & Murakami, K. (2022). Molecular Evolution of the *Pseudomonas aeruginosa* DNA GyrAse *gyrA* Gene. *Microorganisms*, 10(8). <https://doi.org/10.3390/microorganisms10081660>
- Saidi, N., Davarzani, F., Yousefpour, Z., & Owlia, P. (2023). Effects of sub-minimum inhibitory concentrations of gentamicin on alginate produced by clinical isolats of *Pseudomonas aeruginosa*. *Advanced Biomedical Research*, 12(1). https://doi.org/10.4103/abr.abr_389_21
- Salas-Jara, Maria Jose., Ilabaca, Alejandra., Vega, Marco Dan Garcia, Apolinaria. 2016. Biofilm Forming Lactobacillus: New Challenges For The Development Of Probiotics. *Microorganisms*. 4(35) : 1-14.
- Seto Prasetyo, D., Ibrahim, F., Bela, B., & Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia, B. (n.d.). *Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem In Vitro Assays of Several Antipseudomonal Agent Combinations against Carbapenem-Resistant Pseudomonas aeruginosa*. <https://doi.org/10.2>
- Sharma, D., Misba, L., & Khan, A. U. (2019). Antibiotics versus biofilm: An emerging battleground in microbial communities. In *Antimicrobial Resistance and Infection Control* (Vol. 8, Issue 1). BioMed Central Ltd. <https://doi.org/10.1186/s13756-019-0533-3>
- Shauder, S.; Shokat, K.; Surette, M.G.; Bassler, B.L. 2001. The Luxs Family Of Bacterial Autoinducers: Biosynthesis Of A Novel Quorum-Sensing Signal Molecule. *Mol. Microbiol.* 41: 463–476.

- She, P., Luo, Z., Chen, L., & Wu, Y. (2019). Efficacy of levofloxacin against biofilms of *Pseudomonas aeruginosa* isolatd from patients with respiratory tract infections in vitro. *MicrobiologyOpen*, 8(5). <https://doi.org/10.1002/mbo3.720>
- Shiralizadeh, S., Keramat, F., Hashemi, S. H., Majzoobi, M. M., Azimzadeh, M., Alikhani, M. S., Karami, P., Rahimi, Z., & Alikhani, M. Y. (2023). Investigation of antimicrobial resistance patterns and molecular typing of *Pseudomonas aeruginosa* isolats among Coronavirus disease-19 patients. *BMC Microbiology*, 23(1). <https://doi.org/10.1186/s12866-023-02825-w>
- Skariyachan, S., Sridhar, V. S., Packirisamy, S., Kumargowda, S. T., & Challapilli, S. B. (2018). Recent perspectives on the molecular basis of biofilm formation by *Pseudomonas aeruginosa* and approaches for treatment and biofilm dispersal. In *Folia Microbiologica* (Vol. 63, Issue 4, pp. 413–432). Springer Netherlands. <https://doi.org/10.1007/s12223-018-0585-4>
- Sonia Vidaryo Lameng, I., Nyoman Sri Budayanti, N., Inta Prilandari, L., & Indra Adhiputra, A. (n.d.). 2021. *Antimicrobial Resistance Profi le of MDR & Non-MDR Meropenem-Resistant Pseudomonas aeruginosa Isolats of Patients in Intensive Care Unit of Tertiary Hospital*. 9(3). <https://doi.org/10.20473/ijtid.v9i3.30000>
- Thi, M. T. T., Wibowo, D., & Rehm, B. H. A. (2020). *Pseudomonas aeruginosa* biofilms. In *International Journal of Molecular Sciences* (Vol. 21, Issue 22, pp. 1–25). MDPI AG. <https://doi.org/10.3390/ijms21228671>
- Vatansever, Cansu Dan Turetgen, Irfan. 2018. Investigating The Effects Of Different Physical And Chemical Stress Factors On Microbial Biofilm. *Water SA*. 44 (2) : 308-317.
- Vicente, L., Ferreira Da, R., Filho, S., De, F., Ferreira, A., José, F., Reis, C., Amorim De Britto, C., Levy, C. E., Clark, O., Ribeiro, J. D., & Ferreira, R. (2013). *Pseudomonas aeruginosa* infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment* Infecção por *Pseudomonas aeruginosa* em pacientes com fibrose cística: evidências científicas

sobre o impacto clínico, diagnóstico e tratamento*. In *J Bras Pneumol* (Vol. 39, Issue 4).

Wahyudi, D., Aman, A. T., Handayani, N. S. N., & Soetarto, E. S. (2019). Differences among clinical isolats of *Pseudomonas aeruginosa* in their capability of forming biofilms and their susceptibility to antibiotics. *Biodiversitas*, 20(5), 1450–1456. <https://doi.org/10.13057/biodiv/d200538>

Webster, C. M., & Shepherd, M. (2023). A mini-review: environmental and metabolic factors affecting aminoglycoside efficacy. In *World Journal of Microbiology and Biotechnology* (Vol. 39, Issue 1). Springer Science and Business Media B.V. <https://doi.org/10.1007/s11274-022-03445-8>

WHO (2017). Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in health care facilities. World Health Organization. Available at: <https://www.who.int/infection-prevention/publications/guidelines-cre/en/>.

Wijayanto, S. ., & Bayuseno, A. P. (2014). Analisis Kegagalan Material Pipa Ferrule Nickel Alloy N06025 pada Waste Heat Boiler Akibat Suhu Tinggi Berdasarkan Pengujian: Mikrografi dan Kekerasan. *Jurnal Teknik Mesin*, 2(4), 33–39.

Yang, F., Liu, C., Ji, J., Cao, W., Ding, B., & Xu, X. (2021). Molecular characteristics, antimicrobial resistance, and biofilm formation of *Pseudomonas aeruginosa* isolatd from patients with aural infections in Shanghai, China. *Infection and Drug Resistance*, 14, 3637–3645. <https://doi.org/10.2147/IDR.S328781>

Yin, L., Xi, T., Yang, C., Zhao, J., Sun, Y., Zhao, H., & Yang, K. (2020). Investigation on Corrosion Resistance of Welded Cu-Bearing 304L Stainless Steel Against *Pseudomonas aeruginosa*. *Frontiers in Materials*, 7. <https://doi.org/10.3389/fmats.2020.00102>

Yin, R., Cheng, J., Wang, J., Li, P., & Lin, J. (2022). Treatment of *Pseudomonas aeruginosa* infectious biofilms: Challenges and strategies. In *Frontiers in Microbiology* (Vol. 13). Frontiers Media S.A. <https://doi.org/10.3389/fmicb.2022.955286>

- Yousefpour, Z., Davarzani, F., & Owlia, P. (2021). Evaluating of the Effects of Sub-MIC Concentrations of Gentamicin on Biofilm Formation in Clinical Isolats of *Pseudomonas aeruginosa*. *IRANIAN JOURNAL OF PATHOLOGY*, 16(4), 403–410. <https://doi.org/10.30699/IJP.20201.524220.2584>
- Zakhour, J., Sharara, S. L., Hindy, J. R., Haddad, S. F., & Kanj, S. S. (2022). Antimicrobial Treatment of *Pseudomonas aeruginosa* Severe Sepsis. In *Antibiotics* (Vol. 11, Issue 10). MDPI. <https://doi.org/10.3390/antibiotics11101432>
- Žiemytė, M., Carda-Diéguez, M., Rodríguez-Díaz, J. C., Ventero, M. P., Mira, A., & Ferrer, M. D. (2021). Real-time monitoring of *Pseudomonas aeruginosa* biofilm growth dynamics and persister cells' eradication. *Emerging Microbes and Infections*, 10(1), 2062–2075. <https://doi.org/10.1080/22221751.2021.1994355>